Myelodysplastic Syndromes (Myelodysplastic Syndrome)

Subscribe to Selected New Research on Myelodysplastic Syndromes

3214 relevant articles (224 outcomes, 407 trials/studies) found for this Disease

Description: Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.

Also Known As:

Myelodysplastic Syndrome; Dysmyelopoietic Syndrome; Syndrome, Dysmyelopoietic; Syndrome, Myelodysplastic; Syndromes, Dysmyelopoietic; Syndromes, Myelodysplastic; Dysmyelopoietic Syndromes

Relationship Network

Disease Context: Research Results

Hemic and Lymphatic Diseases

Hematologic Diseases: 1480

Bone Marrow Diseases: 65

Myelodysplastic Syndromes: 3214

Paroxysmal Hemoglobinuria: 720

Refractory Anemia: 405

Sideroblastic Anemia: 245

Related Diseases

1.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
2.	Anemia
3.	Leukemia
4.	Refractory Anemia
5.	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)

Experts

1.	Cortes, Jorge: 25 articles (09/2008 - 07/2002)
2.	Kantarjian, Hagop: 24 articles (09/2008 - 01/2002)
3.	Garcia-Manero, Guillermo: 20 articles (09/2008 - 01/2002)
4.	Kantarjian, Hagop M: 17 articles (09/2008 - 05/2002)
5.	Deeg, H Joachim: 17 articles (03/2008 - 01/2002)
6.	Faderl, Stefan: 15 articles (09/2008 - 08/2002)
7.	Estey, Elihu: 15 articles (02/2007 - 01/2002)
8.	O'Brien, Susan: 14 articles (09/2008 - 01/2002)
9.	Fenaux, Pierre: 14 articles (05/2008 - 01/2004)
10.	Raza, Azra: 13 articles (10/2008 - 03/2002)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Myelodysplastic Syndromes:

1.	Cytarabine (Cytosar-U)FDA LinkGeneric 01/01/1992 - "So far we do not know effective treatment of myelodysplastic syndrome and recommend therefore to test in suitable patients small doses of ARA-C, despite the fact that a favourable response to this treatment can be expected only in about one third of the patients." 07/01/1992 - "The efficacy of low-dose cytarabine given as 10 mg sub-cutaneously 12 hourly for 2 weeks and repeated at 2 to 3 weekly intervals was evaluated prospectively in 15 consecutive patients of myelodysplastic syndrome over a 3 year period. " 07/01/1992 - "Efficacy of low-dose cytarabine therapy in myelodysplastic syndromes." 06/01/1992 - "In patients with myelodysplastic syndromes and excess of blasts (n = 82) remission could be induced in nearly 50% if the drug was given together with low dose cytosine arabinoside (LD-AraC). " 03/01/1996 - "Twenty eight patients of myelodysplastic syndrome (MDS) were treated with low dose cytosine arabinoside to study the effect of this treatment modality. " Order ALL the reference details at left...
2.	ErythropoietinIBA 01/01/1995 - "Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies." 08/01/1991 - "The clearance of a single i.v. bolus of recombinant human erythropoietin from the serum of patients with myelodysplastic syndromes and its effects on erythropoiesis." 06/01/2006 - "An open-label, phase II non-randomised trial was conducted with darbepoetin (DAR), an erythropoiesis-stimulating factor with prolonged half-life, at a weekly dose of 300 mug subcutaneously in 62 anaemic patients with myelodysplastic syndrome (MDS) with an endogenous erythropoietin (EPO) level <500 mU/ml. Most of the patients were classified as low or intermediate 1 according to the International Prognostic Scoring System. " 11/01/2004 - "[A study of erythropoietin use for myelodysplastic syndrome]" 07/01/2002 - "Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patients." Order ALL the reference details at left...
3.	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/01/2002 - "We report a patient with myelodysplastic syndrome (MDS), refractory anaemia with excess blasts in transformation, in whom complete remission (CR) was achieved with the administration of granulocyte colony-stimulating factor (G-CSF). " 11/01/1994 - "To evaluate the safety and efficacy of subcutaneous administration of recombinant human granulocyte colony-stimulating factor in the myelodysplastic syndromes (MDS), 20 patients were given a daily dose of 50 micrograms/m2 of KRN8601 for 4 weeks. " 01/01/1990 - "In vitro marrow hemopoietic cultures were utilized to determine the possible efficacy of recombinant human granulocyte colony-stimulating factor (G-CSF) for treating the refractory cytopenias present in the myelodysplastic syndromes (MDS). " 07/01/1991 - "We conducted a phase II study of the intravenous administration of a glycosylated recombinant human granulocyte colony-stimulating factor (rhG-CSF) for 7-14 d in 41 patients with the myelodysplastic syndromes (MDS). " 07/01/1991 - "A phase II trial of recombinant human granulocyte colony-stimulating factor in the myelodysplastic syndromes." Order ALL the reference details at left...
4.	Thalidomide (Thalomid)FDA Link 08/15/2006 - "BACKGROUND: Thalidomide has shown promise for the treatment of patients with myelodysplastic syndrome. " 03/01/2002 - "Efficacy of thalidomide in the treatment of myelodysplastic syndromes." 08/15/2006 - "CONCLUSIONS: Thalidomide alone, at the schedule and dose levels used in the current study, is not a safe and viable therapeutic option for patients with myelodysplastic syndrome. " 12/01/2005 - "A non-randomised dose-escalating phase II study of thalidomide for the treatment of patients with low-risk myelodysplastic syndromes: the Thal-SMD-2000 trial of the Groupe Français des Myélodysplasies." 04/01/2003 - "A phase II trial was conducted to explore the efficacy and tolerability of combining thalidomide (100 mg/d p.o.) with an erythropoietic growth factor (darbepoietin-alpha 2.25 micro g/kg/d s.c.) in patients with low-to-intermediate-risk myelodysplastic syndromes (MDS). " Order ALL the reference details at left...
5.	Cyclosporine (Ciclosporin)FDA LinkGeneric 01/01/2006 - "BACKGROUND: Successful therapy with ATG and cyclosporine A in some myelodysplastic syndrome (MDS) patients led us to study the existence of T cells attacking autologous hemopoietic cells. " 01/01/2007 - "A multicenter prospective study was carried out to evaluate the efficacy of cyclosporin A (CsA) in 32 patients with myelodysplastic syndromes. " 10/17/2006 - "OBJECTIVE: To evaluate the efficacy of cyclosporin A (CsA) in treatment of myelodysplastic syndromes (MDS). " 07/01/2004 - "Response to cyclosporine therapy in patients with myelodysplastic syndrome: a clinical study of 12 cases and literature review." 08/01/2002 - "Recent studies have shown a good response to immunosuppressive treatment with cyclosporin A (CSA) in patients with the myelodysplastic syndrome (MDS). " Order ALL the reference details at left...
6.	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 12/17/1987 - "Our results showed that GM-CSF is a potent stimulator of hematopoiesis in vivo and may produce hematologic improvement in the short term (8 to 32 weeks of observation) in patients with myelodysplastic syndrome. " 11/01/1992 - "GM-CSF treatment of myelodysplastic syndromes: personal experience and preliminary results of a randomized international study." 05/01/1989 - "The toxicity, pharmacokinetics, and hematologic effects of granulocyte-macrophage colony-stimulating (GM-CSF) were studied in a phase I/II trial of 16 patients with myelodysplastic syndrome (MDS). " 05/01/1989 - "As part of a broad phase I study of recombinant human granulocyte-macrophage colony-stimulating factor (rh GM-CSF), four patients were treated who had myelodysplastic syndrome (MDS) with excess blasts. " 01/01/1989 - "In a phase I/II study, 11 patients with myelodysplastic syndromes (MDS) and severe transfusion-dependent cytopenia were treated with recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) to investigate the effects of rhGM-CSF on normal hematopoiesis and leukemic cells. " Order ALL the reference details at left...
7.	lenalidomide (CC 5013)FDA Link 02/01/2006 - "Importantly, lenalidomide induces significant clinical responses even in patients with relapsed/refractory MM. Therefore, lenalidomide represents a new class of antitumour agents that is useful in the treatment of MM. Lenalidomide has received fast track designation from the FDA for the treatment of MM and myelodysplastic syndromes." 02/01/2008 - "Adjusted dose lenalidomide is safe and effective in patients with deletion (5q) myelodysplastic syndrome and severe renal impairment." 02/10/2005 - "Efficacy of lenalidomide in myelodysplastic syndromes." 04/23/2009 - "Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study." 01/01/2008 - "Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q." Order ALL the reference details at left...
8.	Azacitidine (5 Azacytidine)FDA Link 10/15/2006 - "Azacitidine administered in the outpatient setting is well tolerated and can induce complete hematological remission in patients with myelodysplastic syndromes (MDS). " 03/01/2009 - "Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study." 04/10/2009 - "PURPOSE: Azacitidine (AZA) is effective treatment for myelodysplastic syndromes (MDS) at a dosing schedule of 75 mg/m(2)/d subcutaneously for 7 days every 4 weeks. " 03/01/2007 - "5-Azacytidine, a demethylating drug, is effective in the treatment of myelodysplastic syndromes when administered at a low-dose, subcutaneously. " 08/01/2005 - "Based on promising results in Phase I-II testing, azacitidine entered Phase III testing in all subtypes of myelodysplastic syndromes. " Order ALL the reference details at left...
9.	Tretinoin (Retinoic Acid)FDA LinkGeneric 01/01/1986 - "The results support earlier reports that retinoic acid might be useful in the treatment of the myelodysplastic syndrome. " 06/01/2005 - "Treatment of myelodysplastic syndrome with isolated del(5q) including bands q31-q33 with a combination of all-trans-retinoic acid and tocopherol-alpha: a phase II study." 08/01/1993 - "PURPOSE: We conducted a study to evaluate the tolerance to and biologic effects of all-trans retinoic acid in patients with myelodysplastic syndrome. " 03/01/1988 - "A double-blind, placebo-controlled randomized trial of 13-cis retinoic acid was performed to determine if the drug has a therapeutic effect in patients with myelodysplastic syndromes (MDS). " 04/07/2009 - "OBJECTIVE: To investigate the long-term effects of androgen combined with low dose all-trans-retinoic acid on myelodysplastic syndrome (MDS). " Order ALL the reference details at left...
10.	fludarabineIBA 02/01/2008 - "Forty-three AML or high-risk myelodysplastic syndrome (MDS) patients were treated with a fludarabine and low-dose total-body irradiation (TBI)-based pretransplantation regimen. " 03/01/2006 - "[Inhibition effect of fludarabine on the growth of myelodysplastic syndrome cell line MUTZ-1 and its mechanism]" 01/01/2001 - "First line therapy with fludarabine combinations in 42 patients with either post myelodysplastic syndrome or therapy related acute myeloid leukaemia." 04/01/2006 - "We report a high incidence of myelodysplastic syndrome (MDS)/acute myeloid leukaemia (AML) in patients entered into the preceding Medical Research Council Chronic Lymphocytic Leukaemia Pilot study of autografting [corrected] Of 115 newly diagnosed patients treated with fludarabine, 65 patients proceeded to autologous transplant. " 10/01/2001 - "A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome." Order ALL the reference details at left...

Therapies and Procedures

1.	Drug Therapy (Chemotherapy) 10/01/1997 - "Most patients with myelodysplastic syndromes (MDSs) who achieve a complete remission under aggressive chemotherapy develop a recurrence within 18 to 24 months. " 08/01/2000 - "Standard antileukemic chemotherapy induces complete remission in approximately half of patients with high-risk (HR) myelodysplastic syndrome (MDS). " 07/01/2009 - "Patients with AML after previous chemotherapy or radiation therapy had a higher morphologic remission rate compared with those arising from myelodysplastic syndrome or myeloproliferative disease (82% vs 62%; P = .027). " 09/01/2000 - "Long-term remission after intensive chemotherapy in advanced myelodysplastic syndromes is generally associated with restoration of polyclonal haemopoiesis." 07/01/1998 - "From the hematologic findings, the myelodysplastic syndrome had been in partial remission after chemotherapy without any sign of relapse or exacerbation. " Order ALL the reference details at left...
2.	Bone Marrow Transplantation (Transplantation, Bone Marrow) 11/01/1997 - "Allogeneic bone marrow transplantation is an effective treatment for myelodysplastic syndromes, providing a probable cure in about one-third of cases overall. " 08/01/2003 - "We report a patient with myelodysplastic syndrome who underwent an allogeneic bone marrow transplantation during the first remission. " 03/01/2006 - "[Study on unrelated donor allogeneic bone marrow transplantation with Bu-CY2 conditioning regimen for myelodysplastic syndrome]" 04/01/2004 - "The purpose of this study was to evaluate the role of allogeneic bone marrow transplantation (BMT) in children with myelodysplastic syndrome (MDS). " 07/01/1996 - "Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients Société Française de Greffe de Moelle." Order ALL the reference details at left...
3.	Transplantation (Transplant Recipients) 01/01/2000 - "The most important findings are no early transplantation-related mortality, remission inversion in a majority of patients, and so far no cases of secondary myelodysplastic syndromes (MDS) acute myelogenous leukaemias (AML). " 04/01/2009 - "In a multivariate analysis significant factors for relapse were not being in complete remission at the time of transplantation (p=0.002), abnormal cytogenetics (p=0.005), higher patients' age (p=0.03) and therapy-related myelodysplastic syndrome (p=0.04), while higher non-relapse mortality was influenced by higher patients' age. " 01/01/2002 - "The objectives of this study were to develop transplantation regimens for patients with advanced myelodysplastic syndrome (MDS) that would be associated with low transplantation-related mortality and improved relapse-free survival. " 04/01/2006 - "The efficacy of unrelated cord blood transplantation for adult myelodysplastic syndrome." 06/01/2004 - "To explore feasibility and efficacy of unrelated HLA matched donor marrow transplantation in treatment of myelodysplastic syndrome, one case (male, 31 years old) of myelodysplastic syndrome-refractory cytopenia with multilineage dysplasia (MDS-RCMD) has been received unrelated HLA-matched donor transplantation. " Order ALL the reference details at left...
4.	Stem Cell Transplantation 06/01/2008 - "(3) The only potential cure for myelodysplastic syndromes is allogeneic haematopoietic stem cell transplantation but this is not always feasible. " 11/01/2009 - "Using nonmyeloablative regimens allogeneic stem cell transplantation could be offered to elderly patients, the majority of patients with acute myeloid leukaemia and myelodysplastic syndromes. " 02/01/2009 - "The optimal therapy for myelodysplastic syndrome (MDS) is allogeneic bone marrow (BM) or blood (BSC) stem cell transplantation (SCT), although outcomes are limited by nonrelapse mortality (NRM) and relapse. " 02/01/2009 - "IPSS poor-risk karyotype as a predictor of outcome for patients with myelodysplastic syndrome following myeloablative stem cell transplantation." 01/01/2009 - "Allogeneic stem cell transplantation is the only known curative therapy for myelodysplastic syndromes (MDS). " Order ALL the reference details at left...
5.	Hematopoietic Stem Cell Transplantation 06/01/2009 - "This study was purposed to explore the efficacy of hematopoietic reconstitution and survival of patients with myelodysplastic syndrome (MDS) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). " 12/01/2009 - "BACKGROUND: Although hematopoietic stem cell transplantation (HSCT) is offered as a curative therapy for pediatric myelodysplastic syndrome (MDS), it may cause severe complications and mortality. " 06/01/2009 - "[Allogeneic hematopoietic stem cell transplantation in 6 patients with myelodysplastic syndrome]" 05/01/2009 - "The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome." 02/01/2009 - "Clinical research examining the role of hematopoietic stem cell transplantation (SCT) in the therapy of myelodysplastic syndromes (MDS) in adults is presented and critically evaluated in this systematic evidence-based review. " Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Myelodysplastic Syndromes

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 224 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>